- Home
- KIM vs IONS Comparison
KIM vs IONS Comparison
Compare KIM & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KIM
- IONS
- Stock Information
- Founded
- KIM 1958
- IONS 1989
- Country
- KIM United States
- IONS United States
- Employees
- KIM N/A
- IONS N/A
- Industry
- KIM Real Estate Investment Trusts
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- KIM Real Estate
- IONS Health Care
- Exchange
- KIM Nasdaq
- IONS Nasdaq
- Market Cap
- KIM 14.1B
- IONS 12.3B
- IPO Year
- KIM 1991
- IONS 1991
- Fundamental
- Price
- KIM $20.70
- IONS $82.94
- Analyst Decision
- KIM Buy
- IONS Strong Buy
- Analyst Count
- KIM 10
- IONS 21
- Target Price
- KIM $24.20
- IONS $80.71
- AVG Volume (30 Days)
- KIM 5.4M
- IONS 3.2M
- Earning Date
- KIM 10-30-2025
- IONS 10-29-2025
- Dividend Yield
- KIM 5.03%
- IONS N/A
- EPS Growth
- KIM 57.13
- IONS N/A
- EPS
- KIM 0.83
- IONS N/A
- Revenue
- KIM $2,123,057,000.00
- IONS $966,957,000.00
- Revenue This Year
- KIM $4.86
- IONS $27.96
- Revenue Next Year
- KIM $3.18
- IONS $2.33
- P/E Ratio
- KIM $24.84
- IONS N/A
- Revenue Growth
- KIM 8.14
- IONS 20.41
- 52 Week Low
- KIM $17.93
- IONS $23.95
- 52 Week High
- KIM $25.83
- IONS $82.95
- Technical
- Relative Strength Index (RSI)
- KIM 49.13
- IONS 71.14
- Support Level
- KIM $19.86
- IONS $71.83
- Resistance Level
- KIM $20.83
- IONS $74.50
- Average True Range (ATR)
- KIM 0.33
- IONS 3.30
- MACD
- KIM 0.08
- IONS 0.85
- Stochastic Oscillator
- KIM 84.97
- IONS 97.05
About KIM Kimco Realty Corporation (HC)
One of the oldest real estate investment trusts in the United States, Kimco Realty owns interests in 567 shopping centers throughout major markets in the US, representing roughly 101 million square feet.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.